Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Antengene, Astrazeneca, Biontech, Cansino, Carsgen, Gannex, GC, Harbour Biomed, Iaso, Idorsia, Innovent, Johnson & Johnson, Pfizer, Qurebio, RDIF, Regeneron, Roche, Sciwind, Very, Wuhan Institute of Biological Products.

New hires and promotions in the biopharma industry in Asia-Pacific, including: Immunoscape, Innocare, Sumitomo Dainippon, Xwpharma.

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: Aivita Biomedical, Altimmune, Ampio, Aslan, Biontech, Chimerix, Constant, Glaxosmithkline, Gtreebnt, I-Mab, Innovation, Innovent Biologics, LG Chem Life Sciences, Neurorx, Novavax, Opthea, Partner, Pfizer, Redhill, Regeneron, Regentree, Revive, Samsung Bioepis, Stero, Takeda, Takis, Theravance, Union.